Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.56 |
| ▸ | MC4R | P32245 | 8/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306027 | 1.00 | IL23R (0.56) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL28714609 | 0.97 | IL23R (0.56) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL30464987 | 0.94 | IL23R (0.57) | IL23RMC4RKISS1R | |
| SCHEMBL647795 | 0.92 | MC4R (0.51) | IL23RMC4RKISS1R | |
| SCHEMBL14117706 | 0.92 | MC4R (0.55) | IL23RMC4RKISS1RMC1R | |
| SCHEMBL29973259 | 0.92 | GLP1R (0.52) | IL23RMC4R | |
| SCHEMBL18891483 | 0.92 | MC4R (0.62) | IL23RMC4RKISS1R | |
| SCHEMBL18891548 | 0.92 | MC4R (0.62) | IL23RMC4RKISS1R | |
| SCHEMBL30464997 | 0.89 | IL23R (0.57) | IL23RMC4RKISS1R | |
| SCHEMBL30464993 | 0.89 | IL23R (0.58) | IL23RMC4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076322-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-09 | — | — | US | disclosed |
| US-7910583-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | IL23R 1526/4885MC4R 333/4885KISS1R 634/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | IL23R 1526/4885MC4R 333/4885KISS1R 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.